Presentation: Next-generation Genetic Medicines

December 3, 2025 by Aldevron

Expanding on comprehensive CRISPR manufacturing solutions

As the demand for next-generation genetic medicines grows, the need for comprehensive CRISPR manufacturing solutions to scale from research to clinical application grows with it. This requires a focus on quality, scalability, and innovation to ensure safe and effective therapeutic development.

In this presentation, Enabling production of next-generation genetic medicines through comprehensive CRISPR manufacturing solutions, Aldevron’s Max Sellman touches on all those elements along with the tools that support a strong manufacturing process.

Sellman discusses the potential made possible by new manufacturing solutions, such as a treatment for “Baby KJ,” who received the world’s first personalized gene editing therapy using CRISPR technology. Sellman provides insight on how the following items can help drive that potential:

• Nanoplasmid^TM HDR templates
• mRNA Cas9 at a cGMP level
• IDT Alt-R^TM HDR Enhancer Protein
• Aldevron Alchemy^TM Cell-free DNA Technology
• Codex® HiCap RNA Polymerase

Additionally, he offers insight into improving cost efficiency, using CleanCap® AG and ARCA Cap technologies. Taken together, all these innovations covered in the presentation can help reduce manufacturing timelines, eliminate unnecessary steps, and improve therapeutic outcomes.

View the Presentation

View the Presentation

• Have questions on this topic? Contact Us
• Learn more about our CRISPR products and services
• Have an idea for a topic? Let us know!

Subscribe to our blog